Enveric Biosciences, Inc. (ENVB) Stock Score, Valuation & Financial Research

Enveric Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ENVB

Enveric Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.49. These figures are a research snapshot, not a buy or sell recommendation.

What Enveric Biosciences, Inc. does

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Enveric Biosciences is a biotechnology company focused on the development of novel small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company operates as a research and development entity, utilizing its proprietary Psybrary platform to discover and advance drug candidates through preclinical and clinical stages, with a business model centered on licensing its intellectual property and drug assets to pharmaceutical partners.

Products and services

  • The company's primary product pipeline includes EB-003, a neuroplastogen candidate for treatment-resistant depression, and EB-002, a synthetic prodrug of psilocin for anxiety disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party contract research organizations to conduct preclinical studies and clinical trials. Source

Competitors and product-market comparisons

  • Compass Pathways — A biotechnology company developing psilocybin-based therapies for mental health conditions. Source
  • MindMed — A clinical-stage biopharmaceutical company developing psychedelic-inspired medicines for brain health. Source

Business strengths to evaluate

  • Proprietary Psybrary platform for drug discovery Source

Business risks and research considerations

  • History of operating losses and uncertainty regarding future profitability Source
  • Dependence on third-party contract research organizations for clinical development Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ENVB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.49
Market capitalization:
6.65M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -8.73M
Free cash flow:
USD -8.14M
Cash:
USD 8.3M
Total debt:
USD 0.00
EPS:
USD -16.46

What stands out

  • Free cash flow is USD -8.14M, negative for the stored period.
  • The balance sheet shows USD 8.3M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.3M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ENVB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ENVB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ENVB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ENVB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ENVB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ENVB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.